DLL3 and small cell lung carcinoma: Therefore, DLL-3 inhibitors now represent a potential therapeutic target approach in NE-high SCLC-A, underlining the importance of the emerging concept that heterogeneity in SCLC is primarily based on neuroendocrine differentiation, molecular subtype, and gene expression profile.